Following the initiation of Doravirine (DOR) regimen among people living with HIV (PLWH), the study will aim to assess effectiveness, discontinuation, and resistance over the 12-month period. Retrospective data from 500 patients is planned to be collected from 6 - 10 European sites. Cohort 1 : 400 patients, 100 treatment naïve and 300 virally suppressed patients switching from a 1st or second line treatment, Cohort 2: 50 patients with NNRTI mutations (other than DOR), Cohort 3: 50 patients with NNRTI mutations (including DOR). The study will be conducted through collaboration with the NEAT ID Network, a well-established network of clinical sites across Europe.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion virologically suppressed patients at week 48 who have remained on DOR.
Timeframe: Week 48 after DOR initiation
Proportion of patients with virologic failure (Cohort 1 - treatment naive)
Timeframe: on or after week 48 after DOR initiation
Proportion of patients with virologic failure (Cohort 2 - treatment suppressed)
Timeframe: up to 12 months after initiation of DOR
Proportion of patients switched for reasons other than virological failure.
Timeframe: up to 12 months after initiation of DOR